Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (2): 187-189    DOI: 10.12891/ceog3315.2017
Original Research Previous articles | Next articles
Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer
J.H. Check1, 2, *(), A. Rosenberg3, D.L. Check2, A. DiAntonio2, H. Rui4, R. Cohen2, G. DiAntonio2
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA
2 Cooper Institute For Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, USA
3 Thomas Jefferson University, Department Of Surgery, Philadelphia, PA, USA
4 Thomas Jefferson University, Department Of Cancer Biology, Philadelphia, PA, USA
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: To determine if serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF), which is present in high levels during normal pregnancy, is present in higher levels in women with breast cancer positive for progesterone receptors. The study would also determine whether the presence or absence of the estrogen receptor in any way modifies PIBF expression. Materials and Methods: PIBF using a research ELISA was evaluated in the follicular phase in 21 women with receptor status as follows: seven with estrogen receptor (ER)+ and progesterone receptor (PR)+, seven with ER- and PR+, and seven with ER+ and PR. Results: The results showed no differences in serum PIBF in the three groups. The serum PIBF levels were no different than historical controls in the follicular phase. Conclusions: Measurement of serum PIBF does not seem to be an important marker to use to either detect women with breast cancer or to help determine tumor virulence or potential specific therapies. If PIBF plays a role in helping cancer cells to escape immune surveillance, it seems that the intracytoplasmic PIBF would be the form most likely operative.
Key words:  Natural killer cells      Intracellular splice variant      Hormonal receptor status      Breast cancer     
Published:  10 April 2017     
*Corresponding Author(s):  J.H. CHECK     E-mail:  laurie@ccivf.com

Cite this article: 

J.H. Check, A. Rosenberg, D.L. Check, A. DiAntonio, H. Rui, R. Cohen, G. DiAntonio. Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 187-189.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3315.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I2/187

[1] Y. Zeng, J. Mao, X. Wang, B. Yin, Z. Shen, C. Di, W. Gu, M. Wu. Mechanism for ginsenoside Rh2-induced apoptosis of triple-negative breast cancer MDA-MB-231 cells[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 99-104.
[2] J.H. Check, J. Aly. Improving the chance of successful implantation – part 2 – Circumventing immune rejection and the fetal semi-allograft[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 9-13.
[3] J.H. Check, R. Cohen. Amelioration of severe generalized idiopathic pruritus in an estrogen deficient woman taking an aromatase inhibitor for breast cancer following treatment with amphetamine salts[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 934-935.
[4] M. de Fátima Guerreiro Godoy, A.C. Pereira de Godoy, J.M. Pereira de Godoy. Effect of exercise while utilizing a device with an arm compression sleeve to reduce lymphedema[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(1): 17-19.
[5] J. H. Check, J. Aly, E. Chang. Improving the chance of successful implantation – part I – embryo attachment to the endometrium and adequate trophoblast invasion[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(6): 787-791.
[6] A.L. Marcos, A.B. Ammar El Gaaied, F.B. Ayed, S.B. Hassen, S. Zervoudis, I. Navrozoglou, F. Pechlivani, G. Iatrakis. Lymphedema of the arm after surgery for breast cancer: new physiotherapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2012, 39(4): 483-488.
[7] G. Iatrakis, C. Iavazzo, S. Zervoudis, A. Koumousidis, C. Sofoudis, T. Kalampokas, N. Salakos. The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients[J]. Clinical and Experimental Obstetrics & Gynecology, 2011, 38(3): 225-227.
[8] M. Erdemoğlu, U. Kuyumcuoğlu, A. Kale. Pregnancy and adnexal torsion: analysis of 20 cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2010, 37(3): 224-225.
[9] J.H. Check. A practical approach to the prevention of miscarriage: part 3 – passive immunotherapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2010, 37(2): 81-83.
[10] J. H. Check, L. Sansoucie, J. Chern, N. Amadi, M. Srivastava, K. Larece. Evidence that progesterone receptor antagonists may help in the treatment of a variety of cancers by locally suppressing natural killer cell activity[J]. Clinical and Experimental Obstetrics & Gynecology, 2007, 34(4): 207-211.
[11] L. Mettler, A. Salmassi, M. Heyer, A. Schmutzier, Th. Schollmeyer, W. Jonat. Perioperative levels of Interleukin- I B and Interleukin-6 in women with breast cancer[J]. Clinical and Experimental Obstetrics & Gynecology, 2004, 31(1): 20-22.
[12] A. O. Mueck, H. Seeger, D. Wallwiener. ‘Pulsed’ estradiol action can stimulate breast cancer cell proliferation[J]. Clinical and Experimental Obstetrics & Gynecology, 2004, 31(1): 23-24.
[13] D. Tamiolakis. Sentinel lymph-node biopsy qualification in breast cancer[J]. Clinical and Experimental Obstetrics & Gynecology, 2003, 30(2-3): 82-84.
[14] J. P. He, M. Friedrich, A. K. Ertan, K. Millier, W. Schmidt. Pain-relief and movement improvement by acupuncture after ablation and axillary lymphadenectomy in patients with mammary cancer[J]. Clinical and Experimental Obstetrics & Gynecology, 1999, 26(2): 81-84.
[15] M. Friedrich, D. Mink, C. Villena-Heinsen, A. Woll-Hermann, S. Wagner, W. Schmidt. The influence of tamoxifen on the maturation index of vaginal epithelium[J]. Clinical and Experimental Obstetrics & Gynecology, 1998, 25(4): 121-124.
No Suggested Reading articles found!